Variantyx
Variantyx is a private molecular diagnostics company operating a proprietary PCR-free whole genome sequencing platform with Genomic Intelligence software to deliver comprehensive clinical genetic testing for rare disorders, reproductive genetics, oncology, neurology, and wellness applications to healthcare providers across North America and Europe.
- Company typePrivate
- Founded2014
- HeadquartersFramingham, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Variantyx does
Variantyx is a private molecular diagnostics company founded in 2014 and headquartered in Framingham, Massachusetts, that provides clinical whole genome sequencing-based genetic testing for rare genetic disorders, reproductive genetics, precision oncology, neurology, and wellness applications. The company operates a proprietary PCR-free whole genome sequencing platform paired with its Genomic Intelligence analytical software, which detects all major clinically relevant variant types (SNVs, structural variants, mitochondrial variants, repeat expansions) from a single sample with reported sensitivity and specificity above 99.9%. Its product portfolio includes the comprehensive Genomic Unity 2.0 test (the only diagnostic combining short-read and long-read sequencing in one report), the Lightning 2.0 rapid genome line delivering results in 5 days or less for NICU/PICU/ICU patients, the OncoAlly hereditary cancer panels, the IriSight reproductive/prenatal testing line, and the Genomic Inform wellness offering, spanning more than 30 distinct SKUs.
Variantyx sells primarily to healthcare providers (geneticists, neurologists, oncologists, obstetricians) through a sales-led go-to-market combining field clinical sales specialists, a Provider Portal for online ordering, and a Clinical Coordination team for fax/phone orders, with mobile phlebotomy coordination and direct-to-patient kit shipping. Tests are billed through commercial insurance, Medicaid, institutional billing, or self-pay, with a Patient Assistance Program available for qualifying commercially insured patients. The company has raised over $125 million in cumulative private financing across multiple rounds since inception, including a $41.5M Series C-2 in February 2022 led by New Era Capital Partners and a $36M round in April 2024 with Peregrine Ventures, Pitango HealthTech, New Era Capital Partners, and Bosch Ventures. Operations span North America and Europe, with the 2024 round explicitly funding further technological and commercial expansion as the market shifts from targeted panels and exomes toward whole genome testing.
Variantyx firmographics
Firmographics- Name
- Variantyx
- Legal name
- Variantyx, Inc.
- Website
- https://variantyx.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Variantyx is a private molecular diagnostics company operating a proprietary PCR-free whole genome sequencing platform with Genomic Intelligence software to deliver comprehensive clinical genetic testing for rare disorders, reproductive genetics, oncology, neurology, and wellness applications to healthcare providers across North America and Europe.
- Ownership category
- akta.pro rank
Variantyx industry classification
Industry- Product category
- Clinical Genetic Diagnostics Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where Variantyx is headquartered
LocationHeadquarters
- HQ city
- Framingham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Variantyx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Genetic Testing Services: Variantyx provides genetic diagnostic testing services to healthcare providers and patients. The company accepts insurance (commercial and Medicaid) and institutional billing, as well as self-pay options. Financial assistance through a Patient Assistance Program is available for patients with commercial insurance meeting certain criteria.
- Laboratory Testing: Clinical laboratory testing services billed through insurance or paid directly by patients/providers. Testing includes comprehensive genomic analyses for rare genetic disorders, reproductive genetics, precision oncology, and wellness.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Insurance billing (commercial and Medicaid) |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Variantyx product offering
Product offeringCore offering
Variantyx is a clinical molecular diagnostics laboratory providing comprehensive genetic testing services based on PCR-free whole genome sequencing. The company delivers a unified clinical report from a single sample that detects all major clinically relevant variant types (SNVs, structural variants, mitochondrial variants, repeat expansions, methylation patterns), replacing multiple traditional tests such as WES, CMA, MLPA, single-gene panels, and PCR/Southern blot. Test products are organized under the Genomic Unity, OncoAlly, IriSight, Lightning, and Genomic Inform brands and are ordered primarily by healthcare providers for rare disease diagnosis, reproductive genetics, hereditary cancer, and wellness applications.
Product overview
Variantyx is a molecular diagnostics company offering a comprehensive portfolio of genetic testing products built on a proprietary whole genome sequencing (WGS) platform paired with Genomic Intelligence® analytical software. The product ecosystem is organized around two main brands: Genomic Unity® for rare genetic disorders, neurology, reproductive, and precision oncology testing, and OncoAlly® for hereditary cancer analysis. The flagship Genomic Unity® 2.0 combines short and long-read genome sequencing technologies. The comprehensive analysis products (Whole Genome, Exome Plus, Exome Analysis) form the core offering, while targeted analyses cover specific conditions (mitochondrial disorders, cardiomyopathy, ataxia, epilepsy, neuropathies, etc.). Rapid testing is available through the Lightning Genome Analysis line with results in 5 days or less. Reproductive genetics are served through the IriSight® brand for prenatal and pregnancy loss testing. Wellness testing is provided via Genomic Inform®.
Differentiator
Problem solved
Functional benefit
Brands
- Genomic Unity: Portfolio of tests for rare genetic disorders including whole genome, exome, and targeted analyses
- OncoAlly
- IriSight
- Genomic Inform
- Lightning
- Genomic Intelligence
Products and services
- Genomic Unity® 2.0 The only whole genome-based diagnostic test that combines short and long-read sequencing technologies in one clinical report, identifying genetic variants that correlate with the patient's phenotype. It is the most comprehensive genomic test in the company's portfolio, designed for healthcare providers diagnosing patients with suspected genetic conditions.
- Genomic Unity® Whole Genome Analysis Comprehensive diagnostic test using a whole genome platform to detect all major clinically relevant variant types from a single sample, replacing WES, CMA, MLPA, and single-gene testing. Ordered by geneticists and other specialists for patients with suspected rare genetic disorders.
- Genomic Unity® Exome Plus Analysis Comprehensive diagnostic test using the whole genome platform to detect all major clinically relevant variant types from a single sample, analyzing patient DNA jointly with parental DNA when family samples are included. Used by geneticists and other specialists for rare disease diagnosis.
- Genomic Unity® Lightning Genome Analysis Rapid diagnostic test for acutely ill individuals in NICU, PICU, or ICU settings, providing a comprehensive diagnostic report in 5 days or less using short-read genome sequencing. Lightning 2.0 variants combine short and long-read sequencing with 27-44 repeat expansion gene analysis and methylation analysis for variant phasing.
- OncoAlly® Comprehensive Hereditary Cancer Analysis Targeted test focusing on 117 genes associated with hereditary cancer, sequencing and analyzing the entire gene for comprehensive variant detection. Used by oncologists and genetic counselors to assess hereditary cancer risk in patients.
- IriSight® Comprehensive Prenatal Analysis Comprehensive prenatal diagnostic test using the whole genome platform for fetal DNA analysis jointly with parental DNA, replacing WES, CMA, MLPA, and single-gene testing. Ordered by obstetricians, maternal-fetal medicine specialists, and geneticists for pregnancies at elevated risk.
- Genomic Inform® Wellness Testing Wellness predictive screening test providing information about risks across multiple health areas including cancer, neurological disorders, metabolic disorders, heart conditions, and carrier status. Aimed at healthy adults seeking predictive genetic insights.
Quantifiable outcome
- 44% diagnostic yield in neonate cases (157 cases), increasing to 48% for classic NICU indications and 71% for select phenotypes
- +2 more outcomes
Companies that use Variantyx
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Variantyx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Variantyx partnerships and signals
Strategic signalScale indicators6 records
Recent moves6 records
Expansion highlights5 records
Variantyx competitors and assessment
Company assessmentDirect peers
- GeneDx: GeneDx (a subsidiary of Exact Sciences) specializes in rare disease and pediatric genetic diagnostics using whole exome and whole genome sequencing. It is the closest competitor to Variantyx in the rare-disorder/NICU rapid WGS market and overlaps directly on rapid NICU testing products.
- Natera: Natera is a major molecular diagnostics company offering reproductive genetic testing ( Panorama, Vistara), oncology (Signatera), and rare disease tests. Overlap with Variantyx in reproductive genetics (IriSight) and hereditary cancer (OncoAlly) makes it a comparable specialty molecular diagnostics peer.
- Ambry Genetics: Ambry Genetics (part of Tempus AI) provides clinical genetic testing across hereditary cancer, rare disease, reproductive health, and whole genome/exome-based testing. Direct overlap with Variantyx across hereditary cancer panels and rare disorder WES/WGS testing.
- Invitae: Invitae (now operating within Labcorp following acquisition) offers comprehensive genetic testing including whole genome sequencing across rare disease, hereditary cancer, and reproductive health. Direct peer to Variantyx's Genomic Unity and OncoAlly product lines.
- Myriad Genetics: Myriad Genetics is an established molecular diagnostics company with strong hereditary cancer and prenatal testing franchises (BRACAnalysis, Foresight, Prequel). It overlaps with Variantyx's OncoAlly hereditary cancer and IriSight reproductive offerings as a competing specialty genetics brand.
Broad incumbents
- Quest Diagnostics: Quest Diagnostics is a large commercial clinical laboratory offering a broad menu including genetic and genomic testing through its Quest Advanced series and Madison clinic. It is a broader incumbent whose scale and payer relationships compete against Variantyx in hospital and integrated delivery network accounts.
- Labcorp: Labcorp is a leading global clinical laboratory network with growing specialty genetics capabilities, including via the Invitae acquisition. It competes with Variantyx across rare disease and hereditary cancer testing at scale with deep payer contracts.
Emerging players
- Fulgent Genetics: Fulgent Genetics offers NGS-based testing across reproductive, oncology, and rare disease genetics with whole genome and exome services. As a smaller, publicly traded specialty molecular diagnostics firm, it is a comparable scale peer competing for similar provider accounts.
- PreventionGenetics: PreventionGenetics (now part of Exact Sciences) is a clinical DNA testing lab offering exome and whole genome sequencing for rare disorders. Comparable to Variantyx in the rare-disease and comprehensive WGS segment, though smaller in scale and specialty breadth.
- PerkinElmer Genomics: PerkinElmer Genomics provides clinical whole genome and exome sequencing, carrier screening, and NIPT services. It is a comparable specialty genetics provider that competes with Variantyx in rare-disease diagnostics and reproductive genetics testing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Variantyx social profiles
Digital presenceVariantyx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Variantyx leadership team
Management profileNumber of profiles
Profiles7 records
Variantyx funding detail
Funding detailFunding overview
Funding rounds10 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Variantyx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Variantyx
What does Variantyx do?
Variantyx is a clinical molecular diagnostics laboratory providing comprehensive genetic testing services based on PCR-free whole genome sequencing. The company delivers a unified clinical report from a single sample that detects all major clinically relevant variant types (SNVs, structural variants, mitochondrial variants, repeat expansions, methylation patterns), replacing multiple traditional tests such as WES, CMA, MLPA, single-gene panels, and PCR/Southern blot. Test products are organized under the Genomic Unity, OncoAlly, IriSight, Lightning, and Genomic Inform brands and are ordered primarily by healthcare providers for rare disease diagnosis, reproductive genetics, hereditary cancer, and wellness applications.
Is Variantyx a public or private company?
Variantyx is a private company. It is classified as venture growth investor backed and is currently operating.
When was Variantyx founded?
Variantyx was founded in 2014. It employs 101 to 250 people.
Where is Variantyx based?
Variantyx is headquartered in Framingham, United States, in the North America region.
How does Variantyx make money?
Two revenue lines are on record. Genetic Testing Services are the primary driver. The others are laboratory Testing.
Who are Variantyx's main competitors?
Direct peers on record are GeneDx, Natera, Ambry Genetics, Invitae and Myriad Genetics. Broad incumbents are Quest Diagnostics and Labcorp. Emerging players are Fulgent Genetics, PreventionGenetics and PerkinElmer Genomics.
Does Variantyx have an API?
No public API is recorded for Variantyx.
What industry is Variantyx in?
Variantyx's product category is Clinical Genetic Diagnostics Services. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 621511 and its SIC code is 8071.